Cargando…
Peg-Grafted Liposomes for L-Asparaginase Encapsulation
L-asparaginase (ASNase) is an important biological drug used to treat Acute Lymphoblastic Leukemia (ALL). It catalyzes the hydrolysis of L-asparagine (Asn) in the bloodstream and, since ALL cells cannot synthesize Asn, protein synthesis is impaired leading to apoptosis. Despite its therapeutic impor...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9503594/ https://www.ncbi.nlm.nih.gov/pubmed/36145567 http://dx.doi.org/10.3390/pharmaceutics14091819 |
_version_ | 1784796002796961792 |
---|---|
author | de Souza Guimarães, Marina Cachumba, Jorge Javier Muso Bueno, Cecilia Zorzi Torres-Obreque, Karin Mariana Lara, Grace Verónica Ruiz Monteiro, Gisele Barbosa, Leandro Ramos Souza Pessoa, Adalberto Rangel-Yagui, Carlota de Oliveira |
author_facet | de Souza Guimarães, Marina Cachumba, Jorge Javier Muso Bueno, Cecilia Zorzi Torres-Obreque, Karin Mariana Lara, Grace Verónica Ruiz Monteiro, Gisele Barbosa, Leandro Ramos Souza Pessoa, Adalberto Rangel-Yagui, Carlota de Oliveira |
author_sort | de Souza Guimarães, Marina |
collection | PubMed |
description | L-asparaginase (ASNase) is an important biological drug used to treat Acute Lymphoblastic Leukemia (ALL). It catalyzes the hydrolysis of L-asparagine (Asn) in the bloodstream and, since ALL cells cannot synthesize Asn, protein synthesis is impaired leading to apoptosis. Despite its therapeutic importance, ASNase treatment is associated to side effects, mainly hypersensitivity and immunogenicity. Furthermore, degradation by plasma proteases and immunogenicity shortens the enzyme half-life. Encapsulation of ASNase in liposomes, nanostructures formed by the self-aggregation of phospholipids, is an attractive alternative to protect the enzyme from plasma proteases and enhance pharmacokinetics profile. In addition, PEGylation might prolong the in vivo circulation of liposomes owing to the spherical shielding conferred by the polyethylene (PEG) corona around the nanostructures. In this paper, ASNase was encapsulated in liposomal formulations composed by 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) or 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) containing or not different concentrations of 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N [methoxy (polyethylene glycol)-2000] (DSPE-PEG). Nanostructures of approximately 142–202 nm of diameter and polydispersity index (PDI) of 0.069 to 0.190 were obtained and the vesicular shape confirmed by Transmission Electron Microscopy (TEM and cryo-TEM). The encapsulation efficiency (%EE) varied from 10% to 16%. All formulations presented activity in contact with ASNase substrate, indicating the liposomes permeability to Asn and/or enzyme adsorption at the nanostructures’ surface; the highest activity was observed for DMPC/DSPE-PEG 10%. Finally, we investigated the activity against the Molt 4 leukemic cell line and found a lower IC(50) for the DMPC/DSPE-PEG 10% formulation in comparison to the free enzyme, indicating our system could provide in vivo activity while protecting the enzyme from immune system recognition and proteases degradation. |
format | Online Article Text |
id | pubmed-9503594 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-95035942022-09-24 Peg-Grafted Liposomes for L-Asparaginase Encapsulation de Souza Guimarães, Marina Cachumba, Jorge Javier Muso Bueno, Cecilia Zorzi Torres-Obreque, Karin Mariana Lara, Grace Verónica Ruiz Monteiro, Gisele Barbosa, Leandro Ramos Souza Pessoa, Adalberto Rangel-Yagui, Carlota de Oliveira Pharmaceutics Article L-asparaginase (ASNase) is an important biological drug used to treat Acute Lymphoblastic Leukemia (ALL). It catalyzes the hydrolysis of L-asparagine (Asn) in the bloodstream and, since ALL cells cannot synthesize Asn, protein synthesis is impaired leading to apoptosis. Despite its therapeutic importance, ASNase treatment is associated to side effects, mainly hypersensitivity and immunogenicity. Furthermore, degradation by plasma proteases and immunogenicity shortens the enzyme half-life. Encapsulation of ASNase in liposomes, nanostructures formed by the self-aggregation of phospholipids, is an attractive alternative to protect the enzyme from plasma proteases and enhance pharmacokinetics profile. In addition, PEGylation might prolong the in vivo circulation of liposomes owing to the spherical shielding conferred by the polyethylene (PEG) corona around the nanostructures. In this paper, ASNase was encapsulated in liposomal formulations composed by 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) or 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) containing or not different concentrations of 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N [methoxy (polyethylene glycol)-2000] (DSPE-PEG). Nanostructures of approximately 142–202 nm of diameter and polydispersity index (PDI) of 0.069 to 0.190 were obtained and the vesicular shape confirmed by Transmission Electron Microscopy (TEM and cryo-TEM). The encapsulation efficiency (%EE) varied from 10% to 16%. All formulations presented activity in contact with ASNase substrate, indicating the liposomes permeability to Asn and/or enzyme adsorption at the nanostructures’ surface; the highest activity was observed for DMPC/DSPE-PEG 10%. Finally, we investigated the activity against the Molt 4 leukemic cell line and found a lower IC(50) for the DMPC/DSPE-PEG 10% formulation in comparison to the free enzyme, indicating our system could provide in vivo activity while protecting the enzyme from immune system recognition and proteases degradation. MDPI 2022-08-29 /pmc/articles/PMC9503594/ /pubmed/36145567 http://dx.doi.org/10.3390/pharmaceutics14091819 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article de Souza Guimarães, Marina Cachumba, Jorge Javier Muso Bueno, Cecilia Zorzi Torres-Obreque, Karin Mariana Lara, Grace Verónica Ruiz Monteiro, Gisele Barbosa, Leandro Ramos Souza Pessoa, Adalberto Rangel-Yagui, Carlota de Oliveira Peg-Grafted Liposomes for L-Asparaginase Encapsulation |
title | Peg-Grafted Liposomes for L-Asparaginase Encapsulation |
title_full | Peg-Grafted Liposomes for L-Asparaginase Encapsulation |
title_fullStr | Peg-Grafted Liposomes for L-Asparaginase Encapsulation |
title_full_unstemmed | Peg-Grafted Liposomes for L-Asparaginase Encapsulation |
title_short | Peg-Grafted Liposomes for L-Asparaginase Encapsulation |
title_sort | peg-grafted liposomes for l-asparaginase encapsulation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9503594/ https://www.ncbi.nlm.nih.gov/pubmed/36145567 http://dx.doi.org/10.3390/pharmaceutics14091819 |
work_keys_str_mv | AT desouzaguimaraesmarina peggraftedliposomesforlasparaginaseencapsulation AT cachumbajorgejaviermuso peggraftedliposomesforlasparaginaseencapsulation AT buenoceciliazorzi peggraftedliposomesforlasparaginaseencapsulation AT torresobrequekarinmariana peggraftedliposomesforlasparaginaseencapsulation AT laragraceveronicaruiz peggraftedliposomesforlasparaginaseencapsulation AT monteirogisele peggraftedliposomesforlasparaginaseencapsulation AT barbosaleandroramossouza peggraftedliposomesforlasparaginaseencapsulation AT pessoaadalberto peggraftedliposomesforlasparaginaseencapsulation AT rangelyaguicarlotadeoliveira peggraftedliposomesforlasparaginaseencapsulation |